Oxford Biomedica names chief development officer
This article was originally published in Scrip
Executive Summary
Oxford BioMedica, a gene and cell therapy company, has named its non-executive director Dr Paul Blake to its executive management team as chief development officer – effective 1 September 2014. Dr Blake joined the board of Oxford BioMedica in January 2010 and will retain his seat alongside his new position. Most recently, Dr Blake was senior vice-president and chief medical officer of Æterna Zentaris, a global biopharmaceutical company focused on oncology and endocrine therapy.
You may also be interested in...
Finding Value Left On The Shelf: Karuna Case Study
PureTech’s gamble to take an older Eli Lilly drug off the shelf to redevelop in a new indication paid off. The company aims to replicate this 'Karuna model' in the near future.
Podcast: NodThera On The Role Of The Brain In Driving Chronic Disease
Alan Watt, CEO of NodThera, a clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, talks to In Vivo about the company’s pipeline and recent data publication in the field of obesity.
Deals Of The Year 2023 Winners Revealed
For In Vivo's 16th annual Deals of the Year contest, we selected 12 nominees in three categories – Top Alliance, Top Financing and Top M&A. The polls are closed, and it is time to reveal the winners.